Novartis Sandoz unit completes Fougera purchase

Published



Swiss drugmaker Novartis AG’s Sandoz division has completed its $1.53 billion purchase of dermatology drug maker Fougera Pharmaceuticals.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.